Log in
Enquire now
‌

US Patent 11377469 CD73 inhibitors

Patent 11377469 was granted and assigned to ORIC Pharmaceuticals on July, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
ORIC Pharmaceuticals
ORIC Pharmaceuticals
Current Assignee
ORIC Pharmaceuticals
ORIC Pharmaceuticals
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11377469
Patent Inventor Names
Daqing Sun0
Valeria R. Fantin0
Tatiana Zavorotinskaya0
Qiuping Ye0
John Eksterowicz0
Jared Moore0
Erica L. Jackson0
Xiaohui Du0
Date of Patent
July 5, 2022
Patent Application Number
16760380
Date Filed
November 2, 2018
Patent Citations
‌
US Patent 10239912 Modulators of 5′-nucleotidase, ecto and the use thereof
0
‌
US Patent 11028120 CD73 inhibitors
0
‌
US Patent 11130778 CD73 inhibitors
0
Patent Citations Received
‌
US Patent 12018043 CD73 inhibitors
0
Patent Primary Examiner
‌
Eric Olson
CPC Code
‌
C07H 19/23
‌
A61K 31/706
‌
A61K 31/7064

Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11377469 CD73 inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.